Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002061 · ClinicalTrials.gov registry record · NA

A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy

A NA study of HIV Infections and Lymphatic Disease, sponsored by Newport Pharmaceuticals International.

Completed
Registry status
NA
Development phase
1
Study location

NCT00002061: Completed NA study of HIV Infections and Lymphatic Disease, sponsored by Newport Pharmaceuticals International.

NCT00002061 is a NA study of HIV Infections and Lymphatic Disease that has completed, run by Newport Pharmaceuticals International. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002061, a NA study of HIV Infections and Lymphatic Disease, has completed, sponsored by Newport Pharmaceuticals International.

COMPLETED
Registry status
NA
Development phase
1
Study location

Study Summary

The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of the 28 days of treatment), measured by one or more of the following immunologic parameters: * Increase in natural killer (NK) cell activity. * Increase in total T-cells (OKT-11). * Increases in absolute number and percentages of T-helper cells (OKT-4).

Conditions Studied

HIV Infections Lymphatic Disease

Interventions

  • DRUG Inosine pranobex

Study Locations (1)

California

  • Newport Pharmaceuticals International Inc - Laguna Hills

Trial Details

FieldValue
Phase NA
Newport Pharmaceuticals International

6 total trials

What the finished NCT00002061 record still lists

NCT00002061 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Inosine pranobex is the first listed.

NCT00002061 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00002061 about?

NCT00002061 is a clinical study titled "A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Immunodepressed Patients With Uncomplicated Generalized Lymphadenopathy". The objective of this Phase III, randomized, double-blind, placebo-controlled study in patients with immunologic deficiency is to determine the effect of isoprinosine in producing an immuno-restorative response within the study observation period (including the 2-month period following cessation of ...

What is the current status of trial NCT00002061?

This trial is currently completed. It is a NA study.

What conditions does trial NCT00002061 study?

This clinical trial studies the following conditions: HIV Infections, Lymphatic Disease.

What interventions are being tested in trial NCT00002061?

The interventions under investigation include: Inosine pranobex (DRUG).

Who is sponsoring clinical trial NCT00002061?

This trial is sponsored by Newport Pharmaceuticals International, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002061 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Related registry views

Source: ClinicalTrials.gov NCT00002061, the US trial registry maintained by the National Library of Medicine. NCT00002061 (unsized enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.